| XLS |
|
|
Investments in |
Securities |
Loans and other non-current financial assets |
Total |
Equity | ||
|
€ million |
available |
other |
available |
financial | |||
|
Acquisition cost Januar 1, 2007 |
1,606.2 |
24.4 |
5.8 |
0.4 |
30.6 |
1,667.4 |
1.7 |
|
Currency translation |
– |
– |
– |
– |
– |
– |
– |
|
Changes in companies consolidated |
165.6 |
–9,974.7 |
167.5 |
– |
–0.1 |
–9,641.7 |
0.3 |
|
Additions |
16.6 |
9,272.4 |
– |
11.3 |
5.8 |
9,306.1 |
0.3 |
|
Disposals |
–118.3 |
–870.2 |
–167.7 |
– |
–20.1 |
–1,176.3 |
–0.4 |
|
Transfers |
–1,575.4 |
1,575.5 |
– |
– |
– |
0.1 |
–0.1 |
|
December 31, 2007 |
94.7 |
27.4 |
5.6 |
11.7 |
16.2 |
155.6 |
1.8 |
|
|
|
|
|
|
|
|
|
|
Accumulated depreciation |
–22.3 |
–0.1 |
–4.2 |
– |
–0.4 |
–27.0 |
–0.4 |
|
Currency translation |
–0.2 |
– |
–0.3 |
– |
– |
–0.5 |
– |
|
Changes in companies consolidated |
– |
– |
– |
– |
– |
– |
– |
|
Depreciation and impairment losses |
– |
– |
– |
– |
– |
– |
– |
|
Disposals |
3.5 |
– |
– |
– |
– |
3.5 |
– |
|
Fair value adjustments of |
–1.3 |
– |
– |
– |
– |
–1.3 |
– |
|
December 31, 2007 |
–20.3 |
–0.1 |
–4.5 |
– |
–0.4 |
–25.3 |
–0.4 |
|
|
|
|
|
|
|
|
|
|
Net carrying amount as of December 31, 2007 |
74.4 |
27.3 |
1.1 |
11.7 |
15.8 |
130.3 |
1.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquisition cost January 1, 2008 |
94.7 |
27.4 |
5.6 |
11.7 |
16.2 |
155.6 |
1.8 |
|
Currency translation |
0.3 |
– |
– |
–1.6 |
–0.1 |
–1.4 |
–0.3 |
|
Changes in companies consolidated |
– |
–58.5 |
– |
– |
– |
–58.5 |
– |
|
Additions |
19.0 |
57.2 |
0.1 |
– |
6.2 |
82.5 |
0.2 |
|
Disposals |
–3.4 |
–0.4 |
–0.5 |
– |
–6.7 |
–11.0 |
– |
|
Transfers |
– |
– |
– |
– |
– |
– |
– |
|
December 31, 2008 |
110.6 |
25.7 |
5.2 |
10.1 |
15.6 |
167.2 |
1.7 |
|
|
|
|
|
|
|
|
|
|
Accumulated depreciation |
–20.3 |
–0.1 |
–4.5 |
– |
–0.4 |
–25.3 |
–0.4 |
|
Currency translation |
– |
– |
– |
– |
– |
– |
– |
|
Changes in companies consolidated |
– |
–0.1 |
– |
– |
– |
–0.1 |
– |
|
Depreciation and impairment losses |
–29.7 |
– |
– |
– |
– |
–29.7 |
– |
|
Disposals |
– |
– |
0.2 |
– |
0.1 |
0.3 |
– |
|
Fair value adjustments of |
–15.0 |
– |
– |
– |
– |
–15.0 |
– |
|
December 31, 2008 |
–65.0 |
–0.2 |
–4.3 |
– |
–0.3 |
–69.8 |
–0.4 |
|
|
|
|
|
|
|
|
|
|
Net carrying amount as of December 31, 2008 |
45.6 |
25.5 |
0.9 |
10.1 |
15.3 |
97.4 |
1.3 |
As of December 31, 2008, non-current financial assets available for sale (investments) were carried at cost with a book value of € 17.0 million since a market price could not be determined.
The development of the value of minority investments is often dependent on developments on the stock exchanges, which is why the value of minority investments generally declined.
Due to the sustained decline in stock market values, an investment in ZymoGenetics Inc. classified as available for sale was written down by € 29.2 million to the lower fair value. The corresponding expense has been reported under Exceptional items and relates to the Merck Serono division.
No non-current financial assets were reclassified between the individual categories of financial instruments during the fiscal year. The following amounts arising from non-current financial assets classified as “available-for-sale” were recognized in equity as of the balance sheet date:
| XLS |
|
€ million |
Available |
Available |
Total |
Available |
Available |
Total |
|
Fair values/ |
45.6 |
0.9 |
46.5 |
74.4 |
1.1 |
75.5 |
|
Amortized |
–59.7 |
–0.9 |
–60.6 |
–73.5 |
–1.1 |
–74.6 |
|
Unrealized gains/losses |
–14.1 |
– |
–14.1 |
0.9 |
– |
0.9 |
A statement of the Merck Group’s equity interests is filed with the electronic Federal Gazette and can be accessed at www.ebundesanzeiger.de. Major companies of the Merck Group as of December 31, 2008 are presented in the following table:
| XLS |
|
Major companies of the Merck Group by region |
Direct equity |
Sales* |
Profit |
Net equity* |
Employees | ||
| |||||||
|
|
|
|
|
|
| ||
|
Germany/Europe |
|
|
|
|
| ||
|
Merck KGaA, Darmstadt, Germany |
Parent company |
2,367.8 |
63.0 |
4,720.5 |
9,068 | ||
|
Ares Trading SA, Aubonne, Switzerland |
100.00 |
2,365.5 |
86.5 |
222.7 |
99 | ||
|
Laboratoires Serono SA, Coinsins, Switzerland |
100.00 |
1,444.9 |
–115.6 |
8,628.0 |
640 | ||
|
Merck Serono S.p.A., Rome, Italy |
96.72 |
1,128.2 |
67.1 |
298.9 |
647 | ||
|
Merck Lipha Santé S.A.S., Lyon, France |
100.00 |
529.2 |
29.2 |
58.2 |
486 | ||
|
Merck Santé S.A.S., Lyon, France |
100.00 |
489.1 |
99.2 |
295.9 |
1,145 | ||
|
Merck Pharma GmbH, Darmstadt, Germany |
100.00 |
404.5 |
– |
– |
147 | ||
|
Merck Farma y Quimica S.L., Madrid, Spain |
100.00 |
388.8 |
41.4 |
132.1 |
864 | ||
|
Merck Serono UK, West Drayton, United Kingdom |
100.00 |
147.5 |
12.1 |
1.7 |
205 | ||
|
Merck CHC France Group, Lyon, France |
100.00 |
104.2 |
7.2 |
44.4 |
211 | ||
|
Laboratoire Théramex S.A.M., Monaco |
99.88 |
93.2 |
9.7 |
20.6 |
370 | ||
|
Seven Seas Group, Hull, United Kingdom |
100.00 |
81.4 |
3.8 |
10.4 |
340 | ||
|
Merck AG, Zug, Switzerland and Darmstadt, Germany |
100.00 |
– |
74.0 |
1,761.9 |
– | ||
|
|
|
|
|
|
| ||
|
North America |
|
|
|
|
| ||
|
EMD Serono US Group, Rockland, MA United States |
100.00 |
689.2 |
13.1 |
227.8 |
810 | ||
|
EMD Chemicals, Inc., Gibbstown, NJ United States |
100.00 |
231.3 |
4.0 |
244.6 |
950 | ||
|
EMD Serono Canada Inc., Mississauga, Canada |
100.00 |
77.6 |
1.7 |
14.4 |
95 | ||
|
|
|
|
|
|
| ||
|
Latin America |
|
|
|
|
| ||
|
Merck S.A., Rio de Janeiro, Brazil |
100.00 |
251.2 |
13.0 |
52.4 |
1,132 | ||
|
Merck, S.A. de C.V., Estado de México, Mexico |
100.00 |
174.5 |
20.3 |
47.9 |
977 | ||
|
Merck Venezuela Group, Caracas, Venezuela |
100.00 |
106.7 |
21.2 |
29.8 |
276 | ||
|
Ares Trading Uruguay S.A., Montevideo, Uruguay |
100.00 |
93.4 |
39.6 |
20.6 |
23 | ||
|
Merck S.A., Bogota, Colombia |
100.00 |
69.5 |
2.8 |
25.3 |
577 | ||
|
Merck Quimica Argentina S.A.I.C., Buenos Aires, Argentina |
100.00 |
65.5 |
–2.8 |
6.0 |
356 | ||
|
|
|
|
|
|
| ||
|
Asia, Africa, Australasia |
|
|
|
|
| ||
|
Korean companies, South Korea |
100.00 |
397.9 |
69.9 |
88.6 |
361 | ||
|
Merck Ltd., Tokyo, Japan |
100.00 |
333.7 |
28.4 |
105.7 |
468 | ||
|
Taiwanese companies, Taiwan |
100.00 |
327.8 |
30.6 |
89.6 |
390 | ||
|
Merck Pharmaceutical (HK) Co., Ltd., Hong Kong, China |
100.00 |
123.1 |
3.5 |
2.5 |
37 | ||
|
Merck Ltd., Mumbai, India |
51.00 |
61.2 |
9.6 |
72.3 |
1,072 | ||
|
PT Merck Tbk, Jakarta, Indonesia |
86.65 |
44.7 |
7.0 |
21.5 |
782 | ||
back
